{"id":"etavopivat-tablets-high-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Elevated uric acid levels"},{"rate":null,"effect":"Gout"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etavopivat is an Nrf2 activator that enhances the expression of antioxidant response elements and cytoprotective genes in erythrocytes. By boosting cellular antioxidant capacity, it reduces oxidative stress-induced hemolysis, particularly in conditions like sickle cell disease where red blood cells are vulnerable to oxidative damage. This mechanism helps stabilize red blood cell integrity and improve hemoglobin levels.","oneSentence":"Etavopivat activates the Nrf2 (nuclear factor erythroid 2-related factor 2) pathway to increase antioxidant defenses and reduce hemolysis in red blood cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:42.111Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Sickle cell disease"},{"name":"Beta-thalassemia"}]},"trialDetails":[{"nctId":"NCT04624659","phase":"PHASE3","title":"A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Forma Therapeutics, Inc.","startDate":"2021-01-29","conditions":"Sickle Cell Disease","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["FT-4202"],"phase":"phase_3","status":"active","brandName":"Etavopivat Tablets High dose","genericName":"Etavopivat Tablets High dose","companyName":"Forma Therapeutics, Inc.","companyId":"forma-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etavopivat activates the Nrf2 (nuclear factor erythroid 2-related factor 2) pathway to increase antioxidant defenses and reduce hemolysis in red blood cells. Used for Sickle cell disease, Beta-thalassemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}